

Yiying Wang

Counsel



yiying.wang@cooley.com

+86 21 6030 0660

Shanghai

Capital Markets
Mergers and Acquisitions
Private Equity
Life Sciences and Healthcare
Asia

Yiying Wang represents companies, investment banks and private equity funds in IPOs in the US and Hong Kong capital markets, cross-border M&A transactions, and various other corporate transactions.

Prior to joining Cooley, Yiying practiced in the Shanghai offices of other leading US law firms and PRC law firm.

Yiying is a native Mandarin speaker and is fluent in English.

Representative Matters:

Capital Markets

- **Leads Biolabs**, a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address unmet medical needs in oncology, autoimmune, and other severe diseases both in China and globally, with a particular focus on diseases that remain untreated by existing therapies, represented by PD-1/PD-L1, on its HK\$1.29 billion Hong Kong IPO
- Joint sponsors and underwriters **Morgan Stanley, Jefferies, CITIC Securities, CICC and CMB International Securities** on HK\$1.64 billion IPO and listing of **Duality Biotherapeutics**, a clinical-stage biotech company dedicated to the discovery and development of next-generation ADC to treat cancer and autoimmune diseases
- Joint sponsors and underwriters **CICC and CMB International Securities** on HK\$1.005 billion IPO and listing of **Zenergy**, a lithium-ion battery manufacturer focusing on the research and development, production and sales of electric vehicle battery products, electrochemical energy storage battery products and aviation battery products
- Joint sponsors and underwriters **CICC and SPDB International** on HK\$583 million Hong Kong IPO of **BrainAurora Medical Technology**, a seasoned player in China's cognitive impairment digital therapeutics (DTx) market
- Joint sponsors and underwriters **Morgan Stanley and CICC** on HK\$335 million IPO and listing of **Taimei Technology**, a healthtech company that delivers advanced digital solutions for the pharmaceutical and medical device industries
- **Jiuyuan Gene Engineering**, a modern biopharmaceutical company, specialized in R&D, manufacture

- and sales of gene engineering, on its HK\$563.9 million Hong Kong IPO
- The sole sponsor **CICC** and other underwriters on HK\$791 million (US\$101 million) IPO and listing of **Laekna**, a leading biotechnology company, on HKEX
- **ImmuneOnco**, a clinical-stage biotech company, on its HK\$319 million Hong Kong IPO, and its HK\$234 million H share placement
- **Akeso Biopharma's** HK\$1.2 billion follow-on offerings
- Joint sponsors and underwriters **Citi** and **Huatai International** on **Cryofocus Medtech's** HK\$210 million IPO and listing on HKEX
- **Asymchem** in its US\$979 million IPO and listing on the HKEX. This is the largest healthcare HK IPO in 2021.
- **Keymed Biosciences** in its US\$400 million IPO and listing on the HKEX
- **Betta Pharmaceuticals Co., Ltd.** in its proposed IPO and listing on the HKEX
- **Jacobio Pharmaceuticals** in its US\$174 million IPO and listing on the HKEX
- **RemeGen** in its US\$515 million IPO and listing on the HKEX
- **Akeso Biopharma** in its US\$383 million IPO and listing on the HKEX
- **Innovent Biologics** in its US\$421 million IPO and listing on the HKEX
- **Goldman Sachs** and **Morgan Stanley** as underwriters in **CStone Pharmaceuticals'** US\$285 million IPO and listing on the HKEX
- Proposed Hong Kong IPO of **Biokin Pharma** and **Shulan Health**
- **CooTek** in its US\$57 million IPO and listing on the NYSE
- **VCredit** in its US\$163 million IPO and listing on the HKEX
- **OneSmart** in its US\$179 million IPO and listing on the NYSE
- Underwriters in **Four Season Education's** US\$101 million IPO and listing on the NYSE
- **Secoo** in its US\$111 million IPO and listing on the NYSE

M&A and Private Equity

- **Asymchem** in its acquisition of the API Pilot Plant and R&D Laboratory at the former Pfizer UK Sandwich Site, which marks the establishment of Asymchem's first Europe-based R&D and manufacturing hub
- **Lupeng Pharmaceutical** in its US\$35 million Series Pre-B financing
- **Pulnovo Medical** in its latest financing round totaling tens of millions of dollars
- **Asymchem** in its agreement to acquire Snapdragon Chemistry, a US-based chemical technology company
- **JD.com** and **JD Finance** in the US\$500 million joint ventures for e-commerce and fintech services in Thailand with Central Group, the largest retail conglomerate in Thailand, and Provident Capital
- **Ctrip.com** in its acquisition of a minority shareholding in mobike Ltd
- **Ctrip.com** in its acquisition of a minority shareholding in a leading internet company
- **Ocean Link**, a private equity fund, in its acquisition of a minority shareholding in Ma Feng Wo
- **Baidu Inc.** in its sales and spin-off of Baidu Waimai
- **Unilever** in its acquisition of a majority shareholding in a leading Chinese water purifier business
- **Alibaba** in its acquisition of a minority shareholding in China Business News
- **Sequoia Capital (China)** in its acquisition of minority shareholdings in various internet companies
- **Yunfeng Capital** in its acquisition of a minority shareholding in an internet company
- **E-House** in its acquisition of a minority shareholding in a wealth management company

Education

Columbia Law School LLM

Peking University Law School LLB

Admissions & Credentials

New York